[EULAR 2017] Systems-Based Investigation of the Anti-Immunogenic Potential of DMARDs for Rheumatoid Arthritis Using Human Primary Cell-Based BioMAP® Phenotypic Profiling

[EULAR 2017] Systems-Based Investigation of the Anti-Immunogenic Potential of DMARDs for Rheumatoid Arthritis Using Human Primary Cell-Based BioMAP® Phenotypic Profiling
Version:
20767

File Name/Number:
2017 EULAR

Year:
2017

Background: Biologics represent a rapidly growing class of approved and investigational drugs routinely used to treat multiple diseases, including inflammatory and rheumatic diseases1. Unfortunately, the success of such therapeutics is undermined by their immunogenicity and the development of anti-drug antibodies (ADA) associated with treatment failure and hypersensitivity reactions2. Methotrexate (MTX) has been shown to reduce the generation of an ADA response3. The ability of other conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) to mitigate unwanted immunogenicity, and prolong efficacy in patients who cannot tolerate methotrexate, is less clear.